OTC:ZIVO
Zivo Bioscience, Inc.
A pre-revenue biotech firm advancing novel therapies for serious diseases, currently funded primarily through strategic partnerships and equity capital raises.
Key Metrics
Investment Thesis
Bull Case
Investors may view ZIVO as a high-risk, high-reward opportunity given its pipeline of novel therapeutics for serious diseases that could yield significant value upon FDA approval and commercial launch. The company's strategic collaborations provide immediate non-dilutive funding streams and de-risk the development process by leveraging partners' manufacturing and distribution capabilities.
Bear Case
The stock carries extreme risk due to a negative shareholders' equity of -$514k, a retained earnings deficit of -$137M, and a current liabilities balance exceeding current assets. Without consistent product revenue or successful clinical trial milestones, the company faces an imminent threat of insolvency or forced dilution through further equity issuance.
About Zivo Bioscience, Inc.
Zivo Bioscience, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing novel therapeutics for serious diseases, primarily operating within the United States and international markets through strategic partnerships. The company's primary revenue stream consists of milestone payments and royalties from collaborations with major pharmaceutical partners to advance its proprietary drug candidates into clinical trials. With minimal current product sales, the firm relies heavily on grant funding, equity issuances, and commercial deals to finance its high-cost research and development pipeline.
Analysis
Management Discussion
The company reported a net loss of $13.4M driven by substantial operating expenses including $10.3M in general and administrative costs and $3.1M in research and development expenditures. Despite generating minimal revenue, the firm secured $5.6M in financing cash flows to offset its -$4.3M operating cash outflow, though this masks a deteriorating liquidity position with a current ratio below 1.0.
Industry Overview
The biopharmaceutical industry is characterized by high R&D expenditures, long development cycles, and significant regulatory hurdles before products reach market. Companies in this space typically require billions in capitalization to bring therapies to patients, making reliance on external partnerships critical for survival and growth.
Financial Statements
Income Statement
Balance Sheet
Cash Flow
| Metric | 2022 | 2023 | 2024 |
|---|---|---|---|
| Revenue | $0 | $27.6K | $157.2K |
| Cost of Revenue | $0 | $16.0K | $108.3K |
| Gross Profit | $0 | $11.6K | $49.0K |
| Operating Expenses | $8.7M | $7.3M | $13.4M |
| Operating Income | $-8.7M | $-7.3M | $-13.4M |
| R&D | $2.2M | $1.4M | $3.1M |
| G&A | $6.5M | $5.9M | $10.3M |
| Stock-Based Comp | $297.7K | $89.5K | $1.5M |
| Other OpEx | $0 | $0 | $0 |
| Non-Operating Income | $0 | $0 | $0 |
| Interest Expense | $13.3K | $23.8K | — |
| Pre-Tax Income | $-8.7M | $-7.3M | $-13.4M |
| Income Tax | $13.3K | $-15.0M | $22.9K |
| Continuing Ops | $-8.7M | $7.8M | $-13.4M |
| Discontinued Ops | $0 | $0 | $0 |
| Net Income | $-8.7M | $7.8M | $-13.4M |
| Minority Interest | $0 | $0 | $0 |
| Net to Common | $-8.7M | $7.8M | $-13.4M |
| Metric | 2022 | 2023 | 2024 |
|---|---|---|---|
| Current Assets | $1.9M | $425.4K | $1.6M |
| Cash & Equivalents | $1.8M | — | — |
| Prepaid Expenses | $102.4K | $147.3K | $90.8K |
| Other Current Assets | $0 | $278.1K | $1.5M |
| Long-Term Assets | $221.3K | $130.3K | $7.7K |
| PP&E (Net) | $0 | $0 | — |
| Operating Leases | $189.3K | $98.3K | $0 |
| Other LT Assets | $32.1K | $32.1K | $7.7K |
| Total Assets | $2.1M | $555.7K | $1.6M |
| Current Liabilities | $2.0M | $2.8M | $2.0M |
| Accounts Payable | $490.7K | $993.1K | $547.1K |
| Current Leases | $99.3K | $106.3K | $0 |
| Other Current Liab | $1.0M | $513.4K | $398.6K |
| Long-Term Liabilities | $105.9K | $0 | $116.2K |
| LT Operating Leases | $105.9K | $0 | $116.2K |
| Other LT Liab | $0 | $0 | $0 |
| Total Liabilities | $2.1M | $2.8M | $2.2M |
| Shareholders' Equity | $-10.6K | $-2.2M | $-514.9K |
| Paid-In Capital | $115.8M | $121.4M | $136.4M |
| Retained Earnings | $-115.8M | $-123.6M | $-137.0M |
| Total L&E | $2.1M | $555.7K | $1.6M |
| Metric | 2022 | 2023 | 2024 |
|---|---|---|---|
| Net Income (CFO) | $-8.7M | $7.8M | $-13.4M |
| Non-Cash Adjustments | $1.9M | $-15.0M | $9.7M |
| Working Capital Changes | $-266.7K | $1.4M | $-638.6K |
| Cash from Operations | $-7.1M | $-5.8M | $-4.3M |
| Cash from Investing | $0 | $0 | $0 |
| Cash from Financing | $0 | $4.3M | $5.6M |
| FX Effect | $0 | $0 | $0 |
| Net Change in Cash | $-7.1M | $-1.5M | $1.3M |
| Beginning Cash | $8.9M | $1.8M | $274.4K |
| Ending Cash | $1.8M | $274.4K | $1.5M |
Frequently Asked Questions
How does Zivo Bioscience, Inc. make money?
Commercial Collaboration Revenue (Milestone payments and royalties from external partners); Research & Development Expenses (Internal discovery and clinical trial costs); General & Administrative Expenses (Corporate overhead and staffing);
What are the main risks for ZIVO?
Severe liquidity constraints with significant retained earnings deficit and limited current assets compared to liabilities; Dependence on successful clinical trial outcomes and external funding sources due to lack of product revenue; Regulatory approval uncertainties for novel drug candidates in a highly competitive therapeutic landscape.
What is ZIVO's competitive advantage?
Strategic partnerships with major pharmaceutical companies providing essential funding and commercialization pathways; Proprietary drug candidates targeting unmet medical needs in serious diseases; Low historical cash burn relative to peer biotech firms when excluding recent financing events.
Related Companies
Not financial advice. All content is for informational purposes only. Data may contain errors. Consult a qualified financial advisor before making investment decisions.